This has been confirmed particularly in patients with lung cancer, in which high expression levels of CDKN1A with wild-type EGFR status was associated with better survival, whereas CDKN1A expression with oncogenic EGFR mutations was correlated with poor outcome [47]. The gene discussed is EGFR; the disease is lung carcinoma.